Continuous Glucose Monitoring-Informed Basal Insulin Optimization System in Adults with Type 2 Diabetes: Initial Evaluation of Efficacy, Safety, and Impact on Patient-Reported Outcomes.

Sean M Oser¹, Chad Crystal², Kazanna C Hames³, Xuan Li³, Peggy Gao³, Margaret A Crawford³, Christian Hicks³, Matthew Gerber⁴, Thibault Gautier⁴, Patricio Colmegna⁴, Lei Yang³, Harsimran Singh³, Matthew L Johnson³, Stayce E Beck⁵

¹University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

²ERA Health Research, Redmond, WA, USA.

³Dexcom, Inc., San Diego, CA, USA.

⁴Dexcom, Inc., Charlottesville, VA, USA.

⁵Dexcom, Inc., San Diego, CA, USA. stayce.beck@dexcom.com.

PubMed DOI

Abstract

INTRODUCTION: Clinical inertia and the complexity of basal insulin titration are major barriers to optimal glycemic control in adults with type 2 diabetes (T2D). A prototype of the Dexcom Smart Basal system known as basal therapy optimization (BTO), a continuous glucose monitoring (CGM)-informed basal insulin optimization system, was evaluated for its efficacy, safety, and impact on patient-report…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.